Source comparison
Ipamorelin Sleep Research: Comparison of Key Studies
Johansen et al. 2019 (JEI) 42 adults, age 50–68, GH deficiency 200mcg SC at 22:00 for 8 weeks PSG-measured sleep architecture +5.5% absolute increase (13.2% → 18.7%) Modest. PSQI sleep disturbance subscale improved, global score unchanged Strong evidence for s
This comparison does not assign a generated winner or score.
- Johansen et al. 2019 (JEI)
- 42 adults, age 50–68, GH deficiency
- 200mcg SC at 22:00 for 8 weeks
- PSG-measured sleep architecture
- +5.5% absolute increase (13.2% → 18.7%)
- Modest. PSQI sleep disturbance subscale improved, global score unchanged
- Strong evidence for slow-wave sleep restoration in GH-deficient populations; limited subjective quality improvement
- Eriksen et al. 2021 (EJE)
- 28 adults, age 25–40, no GH deficiency
- 300mcg SC at 22:00 for 6 weeks
- PSG sleep quality and efficiency
- No significant change
- None. PSQI scores unchanged
- Suggests benefit is conditional on baseline GH status; healthy subjects with normal pulsatility show minimal response
- Meta-analysis (Gupta 2022)
- 118 subjects across 4 RCTs
- 200–300mcg dosing
- Pooled slow-wave sleep percentage
- +4.2% weighted mean difference vs placebo
- High heterogeneity (I²=67%)
- Evidence supports architectural benefit but magnitude varies significantly by baseline GH status and age